Murray TJ - Search Results

1

Strategies for managing the side effects of treatments for multiple sclerosis.

Langer-Gould A, Moses HH, Murray TJ. Langer-Gould A, et al. Among authors: murray tj. Neurology. 2004 Dec 14;63(11 Suppl 5):S35-41. doi: 10.1212/wnl.63.11_suppl_5.s35. Neurology. 2004. PMID: 15596735 Review.

2

IM interferon beta-1a delays definite multiple sclerosis 5 years after a first demyelinating event.

Kinkel RP, Kollman C, O'Connor P, Murray TJ, Simon J, Arnold D, Bakshi R, Weinstock-Gutman B, Brod S, Cooper J, Duquette P, Eggenberger E, Felton W, Fox R, Freedman M, Galetta S, Goodman A, Guarnaccia J, Hashimoto S, Horowitz S, Javerbaum J, Kasper L, Kaufman M, Kerson L, Mass M, Rammohan K, Reiss M, Rolak L, Rose J, Scott T, Selhorst J, Shin R, Smith C, Stuart W, Thurston S, Wall M; CHAMPIONS Study Group. Kinkel RP, et al. Among authors: murray tj. Neurology. 2006 Mar 14;66(5):678-84. doi: 10.1212/01.wnl.0000200778.65597.ae. Epub 2006 Jan 25. Neurology. 2006. PMID: 16436649 Clinical Trial.

3

Rationale and design of the prospective and retrospective observational study of Avonex and Rebif (PROOF) for the treatment of relapsing-remitting multiple sclerosis.

Murray TJ. Murray TJ. Curr Med Res Opin. 2004 Jan;20(1):25-30. doi: 10.1185/030079903125002667. Curr Med Res Opin. 2004. PMID: 14741068

4

Interferon beta-1a for early multiple sclerosis: CHAMPS trial subgroup analyses.

Beck RW, Chandler DL, Cole SR, Simon JH, Jacobs LD, Kinkel RP, Selhorst JB, Rose JW, Cooper JA, Rice G, Murray TJ, Sandrock AW. Beck RW, et al. Among authors: murray tj. Ann Neurol. 2002 Apr;51(4):481-90. doi: 10.1002/ana.10148. Ann Neurol. 2002. PMID: 11921054 Clinical Trial.

5

Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group.

Jacobs LD, Beck RW, Simon JH, Kinkel RP, Brownscheidle CM, Murray TJ, Simonian NA, Slasor PJ, Sandrock AW. Jacobs LD, et al. Among authors: murray tj. N Engl J Med. 2000 Sep 28;343(13):898-904. doi: 10.1056/NEJM200009283431301. N Engl J Med. 2000. PMID: 11006365 Free article. Clinical Trial.

6

A multicenter, open-label, phase II study of the immunogenicity and safety of a new prefilled syringe (liquid) formulation of Avonex in patients with multiple sclerosis.

Phillips JT, Rice G, Frohman E, Vande Gaer L, Scott T, Haas J, Eggenberger E, Freedman MS, Stuart W, Cunha L, Jacobs L, Oger J, Arnold D, Murray TJ, DiBiase M, Jethwa V, Goelz S. Phillips JT, et al. Among authors: murray tj. Clin Ther. 2004 Apr;26(4):511-21. doi: 10.1016/s0149-2918(04)90053-7. Clin Ther. 2004. PMID: 15189748 Clinical Trial.

7

Efficacy and tolerability of intramuscular interferon beta-1a compared with subcutaneous interferon beta-1a in relapsing MS: results from PROOF.

Minagara A, Murray TJ; PROOF Study Investigators. Minagara A, et al. Among authors: murray tj. Curr Med Res Opin. 2008 Apr;24(4):1049-55. doi: 10.1185/030079908x280545. Epub 2008 Feb 29. Curr Med Res Opin. 2008. PMID: 18315940 Clinical Trial.

8

Treating fatigue in patients with MS: one step forward, one step back.

Schwid SR, Murray TJ. Schwid SR, et al. Among authors: murray tj. Neurology. 2005 Apr 12;64(7):1111-2. doi: 10.1212/01.WNL.0000159518.42481.5A. Neurology. 2005. PMID: 15824329 No abstract available.

9

Complementary and alternative medicine for MS.

Murray TJ. Murray TJ. Int MS J. 2006 Jan;13(1):3. Int MS J. 2006. PMID: 16420778

10

The History of Diagnosis and Treatment of MS: a Brief Overview.

Murray TJ. Murray TJ. Curr Neurol Neurosci Rep. 2022 Aug;22(8):545-549. doi: 10.1007/s11910-022-01217-3. Epub 2022 Jun 14. Curr Neurol Neurosci Rep. 2022. PMID: 35699900 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

144 results

Search Page

Filters